BeiGene
BGNE
#881
Rank
HK$172.87 B
Marketcap
HK$1,575
Share price
1.71%
Change (1 day)
4.40%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (BGNE)

Earnings in 2024 (TTM): -HK$6.93 B

According to BeiGene 's latest financial reports the company's current earnings (TTM) are -HK$6.91 B. In 2023 the company made an earning of -HK$9.42 B an increase over its 2022 earnings that were of -HK$13.96 B.The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -HK$6.93 B-26.4%
2023 -HK$9.42 B-32.52%
2022 -HK$13.96 B24.39%
2021 -HK$11.22 B-13.21%
2020 -HK$12.93 B72.69%
2019 -HK$7.49 B36.01%
2018 -HK$5.51 B616.83%
2017 -HK$0.77 B-15.24%
2016 -HK$0.91 B107.91%
2015 -HK$0.44 B

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-HK$0.15 B-97.95%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$1.91 B-72.40%๐Ÿ‡บ๐Ÿ‡ธ USA